Letizia Sidella

Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy

Ilaria Vicenti, Andrea Rosi, Francesco Saladini et al. · Journal of Antimicrobial Chemotherapy · 2012 · 57 citations

Life Sciences, Infectious Diseases, Microbiology +17

Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)

Simona Di Giambenedetto, Massimiliano Fabbiani, Manuela Colafigli et al. · Journal of Antimicrobial Chemotherapy · 2013 · 52 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy

Letizia Porcelli, Gabriella Guida, Anna Elisa Quatrale et al. · Journal of Translational Medicine · 2015 · 45 citations · Full text

Medicine, Oncology, Pharmacology +17

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial

Massimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli et al. · Journal of Antimicrobial Chemotherapy · 2018 · 32 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)

Massimiliano Fabbiani, Annalisa Mondi, Manuela Colafigli et al. · Scandinavian Journal of Infectious Diseases · 2013 · 29 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17